34977 membres inscrits Accès abonné revues  Aide   Newsletter    Me connecter
Les Communiqués
 
 
     Nasdaq OMX
 
Rechercher dans le flux Nasdaq OMX
Rechercher
Novavax Announces Exercise of Over-Allotment Option to Purchase Additional Shares
Fri, 05 02 2016 20:00:00
  GAITHERSBURG, Md., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today (...)
Essilor International: Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2016
Fri, 05 02 2016 17:00:00
Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2016 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des (...)
Essilor International : Nombre total de droits de vote et d'actions composant le capital social au 31 janvier 2016
Fri, 05 02 2016 17:00:00
Nombre total de droits de vote et d'actions composant le capital social au 31 janvier 2016 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) (...)
Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes
Fri, 05 02 2016 14:00:00
iPro2 Professional CGM Provides Information to Help Physicians Optimize Care for Their Patients Regardless of Their Diabetes Therapy MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from (...)
Auris Medical to Present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11
Fri, 05 02 2016 13:00:00
Zug, Switzerland, February 5, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will webcast a live (...)
Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
Fri, 05 02 2016 13:00:00
Amplia MRI(TM) and Compia MRI(TM) CRT-Ds, Approved for Patients with Heart Failure, Can Safely Undergo Full Body MRI Scans DUBLIN - Feb. 5, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received U.S. Food and (...)
Pihlajalinna Plc:The government plans temporary legislation to limit outsourcing contracts
Fri, 05 02 2016 11:45:00
  Pihlajalinna Plc Stock Exchange release 5 February 2016 13.45 EET The government plans temporary legislation to limit outsourcing contracts The Ministry of Social Affairs and Health and the Ministry of Finance prepare temporary (...)
Oriola-KD Corporation's comparative segment information for 2015 and 2014 based on new operating model
Fri, 05 02 2016 06:45:00
Oriola-KD Corporation Stock Exchange Release 5 February 2016 at 8.45 a.m. Oriola-KD Corporation's comparative segment information for 2015 and 2014 based on new operating model Oriola-KD has made changes to its operating model as (...)
Oriola-KD Corporation's Financial Statements Release 2015
Fri, 05 02 2016 06:30:00
Oriola-KD Corporation Stock Exchange Release 5 February 2016 at 8.30 a.m. Oriola-KD Corporation's Financial Statements Release 2015 Financial performance October-December 2015 Invoicing, indicating volume, of the (...)
Fagron NV: Turnover increased 5.8% to ? 473.0 million
Fri, 05 02 2016 06:00:00
REBITDA decreased by 10.0% to ? 106.5 million Exclusive negotiations with cornerstone investor concerning Fagron's financing Regulated information | Consolidated results for the 2015 financial year Waregem (...)
INNATE PHARMA : Number of shares and voting rights of Innate Pharma as at February 3, 2016
Fri, 05 02 2016 06:00:00
Marseille, February 5, 2016 Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or "AMF") charter, (...)
INNATE PHARMA : Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 3 février 2016
Fri, 05 02 2016 06:00:00
 Marseille, le 5 février 2016 Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l'Autorité des marchés financiers, Innate Pharma SA publie le nombre d'actions composant son (...)
argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference
Fri, 05 02 2016 06:00:00
Breda, the Netherlands / Ghent, Belgium, 5 February 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and (...)
Sanofi nomme Muzammil Mansuri à son Comité Exécutif et au poste de Vice-Président Exécutif, Stratégie et Business Development
Fri, 05 02 2016 06:00:00
Sanofi nomme Muzammil Mansuri à son Comité Exécutif et au poste de Vice-Président Exécutif, Stratégie et Business Development Paris, France - Le 5 février 2016 - Sanofi annonce la nomination de Muzammil "Muz" Mansuri (...)
Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development
Fri, 05 02 2016 06:00:00
Sanofi Appoints Muzammil Mansuri to Executive Committee and Executive Vice President, Strategy & Business Development Paris, France - February 5, 2016 - Sanofi announced the appointment of Muzammil "Muz" Mansuri (...)
Abiomed annonce un chiffre d'affaires au T3 2016 de 85,8 millions d'USD, en progression de 38 % par rapport au précédent exercice
Fri, 05 02 2016 01:56:18
L'utilisation auprès des patients aux É tats-Unis a augmenté de 45 % en comparaison annuelle   Abiomed revoit à la hausse ses (...)
Prothena to Report Fourth Quarter and Full Year 2015 Financial Results and Host Webcast Conference Call on February 18
Thu, 04 02 2016 21:05:00
DUBLIN, Ireland, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today (...)
GENFIT ANNONCE SON CALENDRIER FINANCIER POUR 2016
Thu, 04 02 2016 21:04:59
Lille (France), Cambridge (Massachusetts, Etats-Unis), le 4 février 2016 - GENFIT (Euronext : GNFT - ISIN : FR0004163111), société biopharmaceutique engagée dans la découverte et le développement de solutions thérapeutiques et diagnostiques (...)
GENFIT ANNOUNCES ITS FINANCIAL CALENDAR FOR 2016
Thu, 04 02 2016 21:04:59
Lille ( France), Cambridge (Massachusetts, United States), February 4, 2016 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in (...)
RESULTATS 2015 : TRESORERIE DE CLOTURE DE 60 M? ET AVANCEES MAJEURES DANS LE DIAGNOSTIC ET LE TRAITEMENT DE LA NASH
Thu, 04 02 2016 21:01:47
Horizon de trésorerie à début 2017 Résultats cliniques de Phase IIb d'Elafibranor dans la NASH ayant conduit au lancement d'une étude de Phase III dans la même indication (...)
ANNUAL RESULTS 2015: END-OF-YEAR CASH POSITION OF ?60M AND MAJOR PROGRESS IN THE DIAGNOSIS AND THE TREATMENT OF NASH
Thu, 04 02 2016 21:01:47
Cash horizon to early 2017 Phase IIb clinical results for Elafibranor in NASH led to the launch of a Phase III study in the same therapeutic indication Discovery of a diagnostic tool that (...)
DENTSPLY International Schedules Fourth Quarter and Fiscal 2015 Earnings Release and Conference Call
Thu, 04 02 2016 17:35:39
York, PA - February 4, 2016 - DENTSPLY International Inc. (NASDAQ: XRAY) announced that it will release fourth quarter and fiscal 2015 earnings results on Friday, February 12, 2016 at approximately 7:00 a.m. (Eastern Time).  Following the (...)
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 3 February 2016
Thu, 04 02 2016 13:00:46
Bagsværd, Denmark, 4 February 2016 In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo (...)
Photocure ASA: Presentation of the fourth quarter and full year 2015 results
Thu, 04 02 2016 12:42:30
Photocure will present its fourth quarter and full year 2015 report on Thursday 11 February 2016 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET) and representatives from the company will be Kjetil Hestdal, President (...)
Abiomed Announces Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year
Thu, 04 02 2016 12:00:00
U.S. Patient Utilization Grew 45%, Year Over Year   Abiomed Increases Fiscal Year 2016 Revenue Guidance DANVERS, Mass., Feb. (...)
publicités
publicité
 
  KauriWeb

Afficher toutes les thématiques